Development of azithromycin-PLGA nanoparticles: Physicochemical characterization and antibacterial effect against Salmonella typhi

Colloids and Surfaces B: Biointerfaces

Volumn 80, Issue 1, 2010, Pages 34-39

  Mohammadi, Ghobad ^a,b,c   Valizadeh, Hadi ^a,c   Barzegar Jalali, Mohammad ^a,d   Lotfipour, Farzaneh ^a   Adibkia, Khosro ^a,c   Milani, Morteza ^a   Azhdarzadeh, Morteza ^a   Kiafar, Farhad ^a,c   Nokhodchi, Ali ^d,e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Antibacterial; Azithromycin; Nanoparticle; PLGA; Salmonella typhi

Indexed keywords

AMORPHOUS STATE; ANTI-BACTERIAL ACTIVITY; ANTI-MICROBIAL ACTIVITY; ANTIBACTERIAL; ANTIBACTERIAL EFFECTS; ANTIMICROBIAL PROPERTY; AZITHROMYCIN; CONCENTRATION OF; ENTRAPMENT EFFICIENCY; FTIR SPECTROSCOPY; IN-VITRO; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR LEVELS; NANOPRECIPITATION; NANOSCALE SIZE; ORAL ADMINISTRATION; PHYSICO-CHEMICAL CHARACTERIZATION; PHYSICOCHEMICAL PROPERTY; PLGA NANOPARTICLES; POLY LACTIDE-CO-GLYCOLIDE; SALMONELLA TYPHI; SERIAL DILUTIONS; SLOW RELEASE; TWO PHASIS;

CONTROLLED DRUG DELIVERY; DRUG INTERACTIONS; HOLOGRAPHIC INTERFEROMETRY; INFRARED SPECTROSCOPY; MICROORGANISMS; POLYMERS; SALMONELLA; X RAY DIFFRACTION;

NANOPARTICLES;

AZITHROMYCIN; NANOPARTICLE; POLYGLACTIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; SALMONELLA TYPHI; THERMOGRAPHY; X RAY DIFFRACTION; ZETA POTENTIAL;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG COMPOUNDING; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; POLYGLACTIN 910; SALMONELLA TYPHI; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

NEGIBACTERIA; SALMONELLA TYPHI;

EID: 77954145668     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2010.05.027     Document Type: Article

References (31)

1. Pinto-Alphandary H., Andremont A., Couvreur P. Int. J. Antimicrob. Agents 2000, 13:155-168.
2. Page-Clisson M.E., Pinto-Alphandary H., Ourevitch M., Andremont A., Couvreur P. J. Control. Release 1998, 56:23-32.
3. Grislain L., Couvreur P., Lenaerts V., Roland M., Deprez- Decampaneere D., Speiser P. Int. J. Pharm. 1983, 15:335-345.
4. Fawaz F., Bonini F., Maugein J., Lagueny A.M. Int. J. Pharm. 1998, 168:255-259.
5. Fattal E., Youssef M., Couvreur P., Andremont A. Antimicrob. Agents Chemother. 1989, 33:1540-1543.
6. Soppimath K.S., Aminabhavi T.M., Kulkarnia A.R., Rudzinski W.E. J. Control. Release 2001, 70:1-20.
7. Esmaeili F., Hosseini-Nasr M., Rad-Malekshahi M., Samadi N., Atyabi F., Dinarvand R. Nanomed.: Nanotechnol. Biol. Med. 2007, 3:161-167.
8. Jeong Y.I., Na H.S., Seo D.H., Kim D.G., Lee H.C., Jang M., Na S.K., Roh S.H., Kim S.I., Nah J.W. Int. J. Pharm. 2007, 352:317-323.
9. Peng H.S., Liu X.J., Lv G.X., Sun B., Kong Q.F., Zhai D.X., Wang Q., Zhao W., Wang G.Y., Wang D.D., Li H.L., Jin L.H., Kostulas N. Int. J. Pharm. 2008, 352:29-35.
10. Rivera P.A., Martinez-Oharriz M.C., Rubio M., Irache J.M., Espuelas S. J. Microencapsul. 2004, 21:203-211.
11. Piscitelli S.C., Danziger L.H., Rodvold K.A. Clin. Pharm. 1992, 11:137-152.
12. Zhang D., Tan T., Gao L., Zhao W., Wang P. Drug Dev. Ind. Pharm. 2007, 33:569-575.
13. Adibkia K., Sahi Shadbad M.R., Nokhodchi A., Javadzaheh A.R., Barzegar-Jalali M., Barar J., Mohammad G., Omidi Y. J. Drug Target 2007, 15:407-416.
14. Parry C.M. Trans. R. Soc. Trop. Med. Hyg. 2004, 98:413-422.
15. Adibkia K., Omidi Y., Sahi Shadbad M.R., Nokhodchi A., Javadzaheh A.R., Barzegar-Jalali M., Barar J., Maleki N., Mohammad G. J. Ocular Pharm. Ther. 2007, 23:421-432.
16. Boonleang J., Panrat K., Tantana C., Krittathanmakul S., Jintapakorn W. Clin. Ther. 2007, 29:703-710.
17. Shen Y., Yin C., Su M., Tu J. J. Pharm. Biomed. Anal. 2010, 52:99-104.
18. National Committee for Clinical Laboratory Standards Performance Standards for Antibacterial Disk Susceptibility Tests-Sixth Edition 1996: Approved Standards M2-A6 1996, NCCLS, Wayne, PA.
19. Russell A.D., Hugo W.B., Ayliffe G.A.J. Principles and Practice of Disinfection, Preservation and Sterilization 1982, Blackwell Scientific Publication, London, pp. 8-106.
20. Muthu M.S., Rawat M.K., Mishra A., Singh S. Nanomedicine 2009, 5:323-333.
21. Miura H., Onishi H., Sasatsu M., Machida Y. J. Control. Release 2004, 97:101-113.
22. Lu W., Wan J., She Z., Jiang X. J. Control. Release 2007, 118:38-53.
23. Ahsan F., Rivas I.P., Khan M.A., Torres Suá A.I. J. Control. Release 2002, 79:29-40.
24. Z.J. Li, A.V. Trask, US Patent 7,081,525 B2 (2006).
25. M.S.B. Jasanada, I.L. Garcia, F.F. Mari, US Patent 6,451,990 B1 (2002).
26. Barzegar-Jalali M., Adibkia K., Valizadeh H., Siahi Shadbad M.R., Nokhodchi A., Omidi Y., Mohammadi G., Hallaj Nezhadi S., Hasan M. J. Pharm. Pharm. Sci. 2008, 11:167-177.
27. Valizadeh H., Zakeri-Milani P., Barzegar-Jalali M., Mohammadi G., Danesh-Bahreini M.A., Adibkia K., Nokhodchi A. Drug Dev. Ind. Pharm. 2007, 33:45-56.
28. Fonseca C., Simões S., Gaspar R. J. Control. Release 2002, 83:273-286.
29. Ahlin P., Kristl J., Kristl A., Vrecer F. Int. J. Pharm. 2002, 239:273-286.
30. Das S., Suresh P.K., Desmukh R. Nanomed.: Nanotechnol. Biol. Med. 2010, 6:318-323.
31. Mishra B., Bhavesh B.P., Tiwari S. Nanomed.: Nanotechnol. Biol. Med. 2010, 6:9-24.